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Oncolytic virotherapy has shown impressive results in preclinical studies and first promis-
ing therapeutic outcomes in clinical trials as well. Since viruses are known for a long time
as excellent vaccination agents, oncolytic viruses are now designed as novel anticancer
agents combining the aspect of lysis-dependent cytoreductive activity with concomitant
induction of antitumoral immune responses. Antitumoral immune activation by oncolytic
virus infection of tumor tissue comprises both, immediate effects of innate immunity and
also adaptive responses for long lasting antitumoral activity, which is regarded as the most
prominent challenge in clinical oncology. To date, the complex effects of a viral tumor
infection on the tumor microenvironment and the consequences for the tumor-infiltrating
immune cell compartment are poorly understood. However, there is more and more evi-
dence that a tumor infection by an oncolytic virus opens up a number of options for further
immunomodulating interventions such as systemic chemotherapy, generic immunostim-
ulating strategies, dendritic cell-based vaccines, and antigenic libraries to further support
clinical efficacy of oncolytic virotherapy.
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INTRODUCTION
Oncolytic viruses are novel antitumor agents with the ability to
selectively replicate and lyse tumor cells while sparing healthy tis-
sue. This intriguing characteristic is either an inherent feature of
certain virus species or a result of targeted genetic engineering,
which harnesses tumor-specific molecular alterations for virus
replication and tumor cell lysis (1). The ideal and intriguing con-
cept has been that the oncolytic virus infection proceeds through-
out the whole tumor, thereby leading to effective tumor cell lysis
until the rim of malignant tissue is being reached and further infec-
tion is kept in check. Although numerous oncolytic viruses have
been generated according to this concept, first clinical trials did
not meet the high expectations that have been raised by promis-
ing preclinical developments (2). Though clinical benefit by these
first wave oncolytic agents, such as the mutated Adenovirus (Ad)
Onyx-015 has been rather modest, these studies confirmed that
oncolytic viruses can be safely administered in human patients and
may also work synergistically with systemic radio- or chemother-
apy (3). H101, a direct derivative of the E1B55k-deleted Onyx-015,
was approved in China in 2006 being the first clinically applicable
oncolytic virus (4). At the same time, many factors have been rec-
ognized, which severely impair therapeutic efficacy of oncolytic
viruses such as virus neutralization by blood components, ineffec-
tive transduction of tumor tissue, intratumoral stromal barriers
that inhibit virus spread, hypoxic conditions, interstitial pressure,
and finally, the rapid immune-mediated elimination of the virus
from the tumor tissue (5).
Apart from the cytoreductive aspect, oncolytic viruses have
been initially developed for, it has become increasingly clear
during the recent years that virotherapy exerts multiple antitu-
moral activities. These include direct effects by cytotoxic cytokines
released upon infection by tumor-resident or infiltrating immune
cells (6, 7). Also, effects on the tumor vasculature have been
demonstrated (8, 9). In contrast to the notion that the host’s
immune system limits the efficacy of virotherapy by rapid clear-
ance of infection, it has been perceived that collateral induction
of innate and adaptive immune responses against the tumor
essentially contributes to therapeutic efficacy of virotherapy (10).
Oncolytic virus-mediated destruction of tumor tissue activates
innate immune receptors once the immunogenic cell debris is
taken up and cross-presented by antigen-presenting cells. Antigen-
presenting cells are additionally activated by signals coming from
innate cells and the damaged tissue. The local inflammation of
tumor tissue during oncolytic virus infection therefore provides
suitable conditions for the triggering of tumor-directed immune
responses (11, 12). Oncolytic viruses that are currently most
advanced in clinical development have been designed to amplify
the in situ vaccinative and immunostimulatory effect of virus
infection. The GM-CSF-expressing oncolytic vaccinia virus JX-
594 has shown promising results in phase I/II clinical studies
in hepatocellular carcinoma (13). In advanced melanoma, the
GM-CSF-expressing herpes virus T-Vec led to a significant num-
ber of durable responses and improved survival in a phase III
trial in human patients, thus demonstrating clinical efficacy of
virotherapy in human cancer patients (14).
There has been evidence that virotherapy may profit from gen-
eral immunosuppression by increased intratumoral virus spread
and by delayed virus clearance (15). Apart from safety aspects,
the increased immediate tumor response due to oncolysis would
be in this case achieved at the cost of losing effective tumor-
antigen cross priming and the perspective of long-term antitu-
moral efficacy. In this review, we want to deliver a closer look on
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how oncolytic viruses induce and shape tumor-antigen directed
immune responses. First, we want to address the origin of antitu-
moral immune responses on the level of the infected tumor cell by
discussing the role of viral oncolysis for induction of immunogenic
cell death (ICD). The aspect of ICD has also been recently reviewed
in depth by Bartlett et al. providing complementary information
on how armed viruses and combination strategies work to enhance
antitumor immunity (16). In the second part of our review, we
want to shed light on the role of several immune cells popula-
tions that contribute to the tumor microenvironment. Finally, we
want to highlight some current trends and developments exploit-
ing the immunostimulatory and vaccinative potential of oncolytic
virotherapy to raise T cell responses against the tumor mutanome.
ONCOLYTIC VIRUS-MEDIATED CELL DEATH MECHANISMS
Viruses, mainly DNA viruses, need time after cell entry to com-
plete the viral life cycle and have consequently developed elaborate
strategies to hide from being detected by the host’s immune system
(17). The requirement of effective “stealth” mechanisms illustrates
that virus-mediated cell killing can be a highly immunogenic way
for cells to die. This perception has been exploited in vaccinations
for a long time since vaccines can be more potent when delivered
and expressed by viral vectors (18). Due to the fundamental rele-
vance in multiple physiological processes, enormous efforts have
been made to understand the immunological consequences of dif-
ferent kinds of cell death, which have been classified into three
major kinds: apoptosis, necrosis, and autophagy (19). Apoptosis
is mainly characterized by defined morphological changes such as
formation of apoptotic bodies and biochemical signaling such as
caspase activation and loss of mitochondrial membrane integrity.
Flipping of phosphatidylserines to the outer membrane surface
during apoptosis facilitates silent removal of apoptotic bodies by
phagocytes. This process is usually accompanied by release of anti-
inflammatory cytokines to minimize immune-mediated collateral
damage (20). The coordinated cell demise by apoptosis is essen-
tial for normal development and tissue homeostasis and has been
therefore regarded for long time as a non-immunogenic or even a
tolerogenic event. A second cell death type, necrosis, appears to be
a less coordinated process and the biochemical pathways have been
much less intensively studied. Necrosis is characterized by swelling
of organelles and cytoplasm followed by rupture of the plasma
membrane with release of cytoplasmic contents. Since necrosis is
frequently accompanied by release of proinflammatory cytokines
such as tumor necrosis factor-α (TNF-α) (21), and other immune
activating mediators, necrosis has been more or less regarded as
being immunogenic. However, the traditional perspective of non-
immunogenic/tolerogenic apoptosis and immunogenic necrosis
has been challenged by the finding of “immunogenic” apoptosis
in tumor cells, which can be induced by specific chemothera-
pies such as anthracyclines and oxaliplatin (22, 23). When mice
were treated with tumor cells that have been killed by these “ICD”
inducers, long-term immunity against a challenge with the same
tumor could be observed whereas other chemotherapeutic agents
failed to induce antitumoral immunity. Since then, several other
systemically applicable ICD inducers have been described (24).
Oncolytic virus-mediated cell death does not exactly follow
the classical schemes of apoptosis or necrosis but rather displays
specific features of both cell death modalities with some varia-
tion between different oncolytic virus types. Accordingly, terms
like programed apoptosis, necroptosis, pyroptosis, or necrosis-like
programed cell death have been used to describe cell death by dif-
ferent oncolytic virus species, trying to describe the coordinated
manner in which cells are rearranged in the course of the viral
infection cycle, and the membrane disruptive and inflammatory
release of viral progeny and cytoplasmic/nucleic contents during
lysis. Necrosis-like programed cell death has been observed using
oncolytic Ads (25). Though activity of caspases could be observed,
p53 activity and mitochondrial pathways were effectively blocked
whereby execution of cell death was essentially independent of cas-
pase activation. Likewise, programed necrosis was also observed
in cells infected with an oncolytic vaccinia virus. Though some
limited features of apoptosis and autophagy were detectable such
as phosphatidylserine exposure and LC3 lipidation, necrotic mor-
phology predominated and the necrotic process was also identified
as causative cell death modality (26).
Recently, receptor-interacting protein kinases RIP1 and RIP3
have emerged as a decisive switch from immunologically silent
apoptosis to necrotic inflammation (27). Once caspase-8 activ-
ity, located in a receptor-associated complex called necrosome, is
suppressed, e.g., by a pathogen-encoded inhibitor, RIP1 is sta-
bilized, then attracting and phosphorylating RIP3 (28). RIP3
activation phosphorylates the major downstream target mixed
lineage kinase domain-like (MLKL) by phosporylation and trimer-
ization that translocates to the plasma membrane to mediate
Ca2+ influx and initializing membrane rupture (29). RIP1/RIP3-
dependent necroptosis therefore appears to function like a backup
mechanism allowing the elimination of pathogen-infected cells
that cannot undergo apoptosis (30). Necrotic features of RIP3-
dependent cell death are necessary for induction of inflamma-
tion, improved antigen presentation and effective defense against
the pathogen. It has been demonstrated that the highly spe-
cific caspase-8 inhibitor vICA, encoded by cytomegalovirus, pre-
disposes to RIP3-dependent necrosis (31). Additionally, CrmA
related apoptosis inhibitors activate TNFR-dependent necropto-
sis in vaccinia virus infections in mice augmenting clearance of
the virus (32). Interestingly, cytomegalovirus also express a RIP3
inhibitor, vIRA, which blocks this “backup” cell death pathway
to reduce inflammatory responses (33). A downstream target of
the RIP1-RIP3-necrosome in necroptosis is JNK-1 and its sub-
strate c-Jun with a final impact on the production of reactive
oxygen species (ROS) (34). We could show that oncolytic Ad
infection in human tumor cells strongly induced JNK-1 activa-
tion, downstream phosphorylation of c-Jun, and activation of
other stress-activated kinases (35). It has further been shown that
programed necrosis by oncolytic vaccinia virus infection involved
formation of a RIP1/Caspase-8 complex (26). In this study, the rel-
evance of RIP1 in vaccinia virus-induced programed necrosis was
demonstrated by pharmacological inhibition of both RIP1 and
downstream targets including MLKL, which significantly atten-
uated necrotic cell death. Using an oncolytic influenza viruses,
armed with the antitumoral cytokine IL-24, it has been shown
that IL-24 turned cell death, mediated by a TLR3-associated, RIP-
1 containing signaling complex, into a pure apoptotic phenotype
by unleashing caspase-8 activity (36). Though enhanced tumor cell
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killing was observed in vitro, the consequences of this approach on
immunogenicity and antitumoral immune responses in vivo are
unclear.
In summary, the RIP1/RIP3 necrosome plays a central role
in induction of inflammation and virus-mediated ICD and is
therefore an interesting target for more detailed investigations,
and targeted modulation in oncolytic virotherapy. Again, it has
to be considered that enhanced immunogenicity of oncolytic
virus-mediated cell death will probably affect viral spread.
THE ROLE OF AUTOPHAGY IN ONCOLYTIC VIRUS-MEDIATED
ICD
Another cell death type, autophagy, is a process that leads to
self-digestion of organelles after inclusion in cytosolic lysosomes
(autophagolysosomes). Since signs of autophagy also occur as a
reversible process in the context of nutrient starvation, it is not
completely clear whether autophagy is causative for cell death
or is an epiphenomenon of other cell death triggers. However,
autophagy plays a definitive role in triggering immune responses.
Autophagic mechanisms are involved in the clearance of intra-
cellular microbial or viral pathogens not only by intracellular
digestion but also by improved processing of microbial/viral anti-
gens for antigen presentation on MHC I as known for herpes
simplex virus infections (37). Autophagy can be a part of a cel-
lular reaction to infection by oncolytic viruses, which has been
observed first in glioma treatment with oncolytic Ads (38, 39).
Induction of autophagy has also been demonstrated for New-
castle disease virus (NDV) (40). In both cases, investigations
using the autophagy inducer rapamycin suggested that autophagy
augments viral replication and propagation and may lead to
improved antitumor responses (41, 42). An interesting subtype
of autophagy, called mitophagy, has been reported recently (43).
The authors have shown that attenuated measles viruses of the
Edmonton strain exploit selective reduction of mitochondria
via SQSTM1/p62-mediated mitophagy for enhanced viral repli-
cation. Mitophagy resulted in decreased mitochondrion-bound
mitochondrial antiviral signaling protein (MAVS) thus weakening
the innate immune response mediated by RIG-I-like receptors.
In summary, cell death by oncolytic viruses displays signs of
apoptosis, autophagy, and necrosis to a variable extent. What all
oncolytic viruses have in common is the immunogenic nature
of virus-induced cell death (see also Figure 1 for an overview).
The determinants characterizing ICD are summarized in the next
chapter.
INDUCERS AND MEDIATORS OF IMMUNOGENIC CELL
DEATH: DAMPs AND PAMPs
Antigen-presenting cells such as dendritic cells (DC) fulfill a cen-
tral role in triggering effective T cell responses in case of a patho-
genic threat. Antigen-presenting cells are activated when encoun-
tering pathogen-derived structures, called PAMPs (pathogen-
associated molecular patterns), which reflect conserved compo-
nents of microbes and viruses. Classical PAMPs are microbial
DNA with unmethylated CpG, defective viral genomes that occur
during viral lysis, double stranded RNA, single stranded RNA, 5′-
triphospate RNA, lipoproteins, surface glycoproteins, and bacterial
membrane components such as LPS. PAMPs are recognized by
pattern recognition receptors (PRRs) present on innate immune
cells, antigen-presenting cells, and also on epithelial cells. PRR
include toll-like receptors, retinoid acid inducible gene I (RIG-I)-
like receptors (RLRs), AIM like receptors (ALRs), and nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs)
(44). In 1994, the “danger” hypothesis by Polly Matzinger (45)
brought up the idea that, besides the classical feature to distin-
guish between self and non-self, the immune system must be able
to adequately respond to tissue distress, and that this additional
competence requires molecular signaling coming from affected
tissue. According to this hypothesis, molecular danger signal-
ing immediately alerts innate immune cells and facilitates their
attraction to the site where ICD occurred. Furthermore, danger
signaling must activate DCs to provide for the stimulation needed
to activate antigen-specific T cells. A number of molecular fac-
tors called danger-associated molecular patterns or DAMPs have
been described functioning as such danger signals to orchestrate
attraction of innate immune cells, phagocytosis of immunogenic
cell debris, and to activate effective T cell priming. Some DAMPs
are immune activating cytokines such as TNFs or type I inter-
ferons that can be immediately emitted in response to threat.
Other factors are metabolites that create a chemotactic gradient
for innate immune cells corresponding to a “find me” signal. Fur-
ther, DAMPs already reflect signs of structural damage caused by
the infection process. Externalized proteins, more or less linked
to the membrane of the infected cell can provide an “eat me”
signal to attracted phagocytes. When cells undergo immuno-
genic apoptosis, the release of ATP is a known “find me” signal
to promote phagocytic clearance of those cells at a very early
time point (46, 47). ATP is released by Pannexin channels and
sensed by P2Y (2) purinergic receptors on monocytes to facilitate
their attraction to the site of apoptotic cell death. Additionally,
ATP acts on P2X (7) purinergic receptors on DCs, thus activat-
ing the NLRP3 inflammasome (48). ATP has also been described
being released by cells infected by oncolytic viruses (49, 50). In
induction of ICD, ATP can also act synergistically with another
DAMP, cell surface exposed calreticulin or ecto-CRT (51). Cal-
reticulin is under physiological conditions located in the lumen
of the endoplasmic reticulum (ER). However, dying cells exter-
nalize and present calreticulin on their surface where it serves as
a potent “eat me” signal to phagocytes (52). It has been shown
that calreticulin is exposed on the cell surface of lung adenocar-
cinoma cells after treatment with an oncolytic coxsackievirus B3
(50). Ecto-CRT has also been observed with several oncolytic Ads
(49, 53).
When cells succumb to necrosis, they also externalize and
release the high mobility group box 1 (HMGB1) protein into
the cellular environment, which is known for its proinflamma-
tory properties (54). The relevance of HMGB1, Ecto-CRT, and
ATP in characterizing ICD has facilitated reliable high throughput
screens for ICD-inducing agents (55). HMGB1 release has been
observed with multiple oncolytic viruses, e.g., Ad, Vv, and Mv (26,
53, 56, 57).
Further, important DAMPs are released heat shock proteins,
such as HSP70 and HSP90, and uric acid. Heat shock protein
release has been demonstrated to play a role in induction of tumor-
specific immune responses by the oncolytic parvovirus H1 (58).
www.frontiersin.org July 2014 | Volume 4 | Article 188 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Woller et al. From immunogenic cell death to antigenome-targeted vaccination
FIGURE 1 |The figure illustrates the improvedT cell priming in oncolytic
virotherapy. Viral oncolysis of tumor cell induces immunogenic cell death by
accumulation of PAMPs and accompanied by release of DAMPs. PAMPs and
DAMPs activate antigen-presenting dendritic cells that can induce
cytotoxic T cell responses against tumor-associated antigens or neoepitopes,
respectively.
Uric acid is a product of nucleic acid catabolism and constitutively
present in the cytosol of normal cells in high concentrations that
can even rise in stress situations due to increased DNA/RNA degra-
dation. Even the debris of dead cells is able to continue production
and release of uric acid providing a sustained danger signal (59).
It is believed that a chemical phase change to urate microcrys-
tals at supersaturated loci is the actual immune activating event.
Using the oncolytic Ad Telomelysin, it has been shown that infected
tumor cells produced uric acid, which in turn stimulated IFN-γ
and IL-12 secretion by DC and supported the induction of cyto-
toxic T cells (60). The DAMPs described so far represent potent
immune activators in case of immunogenic apoptosis or necro-
sis. However, also cell-intrinsic inhibitors of DAMPs exist. Recent
results showed that the cellular peptidases dipeptidylpeptidase
3 (DPP-3) and thimet oligopeptidase 1 (TOP-1) present in and
released by necrotic cells were able to provide a non-immunogenic
signal and inhib antigen cross presentation (61). Since inhibition
of the peptidases restored immunogenicity and antigen-specific
Tcell priming, interfering with these mechanisms in oncolytic
virus-mediated cell death could be a promising option to enhance
immunogenicity.
THE ROLE OF ER-STRESS IN ONCOLYTIC VIRUS-MEDIATED
ICD
A further important mechanism that provides dying cells with an
immunogenic signature is ER-stress. The ER is a central produc-
tion site for proteins and membrane components involved in the
secretory pathway. The ER is also an important sensor for ER-
stress, a physiological reaction to dysbalanced protein synthesis,
e.g., in the context of viral infections. Under homeostatic condi-
tions, the luminal ER-stress sensors IRE1α, ATF6, and PERK are
bound and silenced by the molecular chaperone Grp78/BiP. Once
unfolded proteins accumulate in the ER due to an unphysiologic
increase in protein synthesis, Grp78/BiP is competitively displaced
from the ER-stress sensors leading to their subsequent activa-
tion for downstream induction of an unfolded protein response
(UPR) (55). Whereas activation of IRE1α and ATF6 leads to
expression of compensatory acting genes, PERK/ATF activation
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facilitates phosphorylation of eIF2α to induce a general stop of
translation until ER-stress has been released. eIF2α-dependent
shutdown of translation is also an intrinsic defense reaction to
prevent that intracellular pathogens from occupying the protein
synthesis machinery for their own purposes. Consistent with this
function, ER-stress can confer a significant immunogenic signal
to dying cells, which has been demonstrated using chemothera-
peutics that are able to directly induce ER-stress (55). According
to the relevance of ER-stress as pathogen sensor, many viruses
have evolved elaborate ways to circumvent or to adopt ER-stress
pathways to their benefit and interfere with ER-stress pathways and
UPR (17). ER-stress pathways are also an interesting target to mod-
ulate the outcome of oncolytic virutherapy and to increase ICD.
Genome-wide RNAi-screens for host factors that modulate viral
oncolysis showed that ER-stress and UPR are highly important
modulators of viral oncolysis by rhabdovirus (62). To confirm the
screening results, the authors showed that inhibition of IRE1α dra-
matically improved rhabdovirus-mediated oncolysis. Accordingly,
ER-stress has been a promising mechanism for pharmacological
interference to support viral oncolysis. Bortezomib is a clinically
approved inhibitor of the 26S proteasome and leads to collat-
eral ER-stress and ICD with both apoptotic and necrotic features.
We showed that low-dose bortezomib enhanced immunogenic
tumor cell killing and antitumoral T cell responses in hepato-
cellular carcinoma models in mice (35). Another study showed
that Reovirus and bortezomib synergistically induced apoptosis
in multiple myeloma (63). In case of oncolytic herpes simplex
virus (oHSV), it could be recently demonstrated that bortezomib-
induced UPR even increased virus replication thus leading to
enhanced, synergistic tumor effects (64).
ONCOLYTIC VIRUS INFECTION DISRUPTS THE TUMOR
MICROENVIRONMENT
Immunogenic cell death is basically the first aspect in innate
and adaptive immune effects that have been recognized as a
central mode of action in virotherapy (65). The tumor microen-
vironment also essentially contributes to the triggering of anti-
tumoral immunity. Tumors not only consist of tumor cells but
also of stromal fibroblasts, endothelial cells and resistant leuko-
cytes which together with the extracellular matrix constitute the
tumor microenvironment. Intratumoral infection by an oncolytic
virus is not only a dramatic impact for tumor cells but is also
disruptive for tissue architecture and immune homeostasis within
the tumor microenvironment. The effect of the tumor stroma to
oncolysis is a most enigmatic and barely understood phenome-
non since fibroblasts are relatively resistant to virus infection and
generate important intratumoral barriers that inhibit virus dis-
tribution. To address these barriers, it has been tried to interfere
with stroma integrity by oncolytic viruses expressing collagenase
and matrix-modifying enzymes (66, 67). The activation of the
innate immune system following intratumoral virus infection
represents the first defense wave of the host reaction to tumor
lysis. Tumor-resident innate immune cells become modulated by
inflammatory cytokines that are immediately released upon con-
tact of macrophages with viral structures (68, 69). Further innate
immune cells invade the damaged tumor tissue and induce an
acute inflammation to fight the viral infection. Neutrophils invade
the oncolytic tumor and contribute to immediate antitumoral
cytotoxic effects (9, 70). Additional neutrophil-activating signals
have been used to increase this effect of oncolytic virotherapy
(71). Interestingly, in case of measles virus, it has been shown that
attenuated, oncolytic viruses can be even better neutrophil acti-
vators compared to their wild-type counterparts (72). Results of
several studies suggested that the innate immune response should
be suppressed to enhance oncolytic virus propagation and intra-
tumoral spread (73–76). It has also been shown with measles virus
that innate immune cytokines can confer resistance to tumor cells
against virus-mediated lysis (77). However, the innate immune
response is an essential interface for triggering of adaptive immune
response including long-term antitumoral T cell responses. It
could be rather promising to selectively address suppressive innate
immune cell subpopulations in oncolytic virotherapy (6). Since
the oncolysis-mediated modulation of the tumor microenvi-
ronment decisively governs the priming of adaptive immune
responses, the individual immune cell types that contribute to
the tumor microenvironment and the immediate reaction to viral
oncolysis need a more detailed description.
MYELOID CELLS
Aside of neutrophils, macrophages and monocytes belong to the
initial defense response by the innate immunity against pathogens.
These populations are highly activated after viral infections,
are capable of phagocytosis, support the professional antigen-
presenting cells, and contribute to adaptive immunity. Within an
intact tumor, secretion of immunosuppressive cytokines deter-
mines the phenotypic differentiation of these innate immune cells
to adopt an immunosuppressive status to promote tumor progres-
sion and metastases (78). Consequently, the immunosuppressive
phenotype of these cells can interfere with therapeutic antitumor
immune activities. Macrophages residing in the tumor microenvi-
ronment have been designated as tumor-associated macrophages
(TAMs) and can be divided into two groups, one showing an
inflammatory M1 phenotype and the other showing, an immune
suppressive M2 phenotype, the latter being overrepresented within
the tumor microenvironment (79). It is known that viral inflam-
mation can polarize macrophages toward an M1 phenotype (80).
This population promotes inflammatory conditions and supports
the triggering of antigen-specific immune response. It has been
shown that TAM depletion by chlodronate liposomes prevent
intratumoral virus clearance resulting in increased replication and
virus spread resulting in improved antitumoral effects (81). Like
macrophages, tumor-associated neutrophils can be either assigned
to an inflammatory N1 phenotype or an immune suppressive
N2 phenotype, respectively (82). Though invading neutrophils
belong to the first infiltrating immune populations at the site of
inflammation (9), the role of neutrophil polarization in oncolytic
virotherapies has not yet been addressed.
In recent years, myeloid-derived suppressor cells (MDSC) pop-
ulation has been described as one of the most important immuno-
suppressive within the tumor microenvironment. These cells have
been observed in primary tumors as well as in metastases of
patients (83, 84). Myeloid suppressor cells are attractive targets
for therapeutic investigations (85). Related to oncolytic virother-
apy, it was shown that the combination with gemcitabine, which is
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a chemotherapeutic agent depleting MDSC populations, increases
antitumoral immune responses (86, 87).
VIROTHERAPY IS A POTENT NK CELL ACTIVATOR
Among the cells of the innate immune system, NK cells play a
crucial role in clearing viral infection and in fighting malignant
cells. Trying to escape from adaptive immune responses by down-
regulation of MHC, virus-infected cells, and tumor cells become a
natural target of NK cells. In line with a role of NK cells in immu-
noediting of tumors, tumor-infiltrating NK cells correlate with a
favorable prognosis in humans (88). NK cells belong to the first
immune cell populations that are activated by a virus-mediated
inflammation in order to identify and directly kill virus-infected
cells (89). This suggests that NK cell inhibition will significantly
support intratumoral spread of oncolytic viruses and effective
tumor lysis. A study using oncolytic VSV showed that the replica-
tion of the virus could be enhanced by NK cell depletion resulting
in more effective tumor killing (74). The supportive effect of NK
cell inhibition was confirmed by the same group by application of
a virus encoding for UL141, which blocks CD155 on infected cells
thereby interfering with NK cell recruitment and activation (90).
Furthermore, it was shown that the NK cell natural cytotoxicity
receptors (NCR) NKp30 and NKp46 were highly activated dur-
ing oHSV resulting in effective killing of oHSV infected cells thus
impeding viral spread and oncolytic therapy (75).
On the other hand, several studies showed an antitumoral effect
of NK cells after oncolytic viral treatment. Depletion studies with
VSV in the B16 melanoma model revealed an NK cell and T cell
dependent tumor regression (91). Furthermore, the remodeling
of the immunosuppressive tumor microenvironment of prostate
cancer by the infection with oncolytic reovirus demonstrated a
strong NK cell involvement in antitumoral immune response (92).
It was also observed that the antitumoral effect of an oncolytic
parapoxvirus ovis (ORFV) was mainly NK cell-mediated (93).
Using an adenovirus expressing IFNβ for systemic NK cell acti-
vation, Suzuki et al. could show that intratumoral virus treatment
in a pancreatic cancer model resulted in strong NK cell-mediated
antitumoral cytotoxicity, when MDSC were eliminated by gemc-
itabine (86). These data illustrate that other immunosuppressive
populations within tumor microenvironment play an important
role in the establishment of antitumoral immunity, which must
be considered for the role of NK cells in oncolytic virotherapy.
Promising reports come from observations on the application as
adjuvant to surgical tumor removal. This is of particular clini-
cal relevance since surgery is still the most frequent therapeutic
option with curative intention. In a first therapeutic approach
using virotherapy as perioperative agent in a surgical stress model,
Tai et al. showed that virotherapy by vaccinia virus or ORFV can
release NK cell suppression during surgical intervention (94, 95).
Virus-mediated NK cell activation effectively inhibited the engraft-
ment of metastatic cells. This finding suggests that NK cells seem to
be in particular efficient to protect against tumorigenic cells when
an established immunosuppressive tumor microenvironment is
lacking. These observations are supported by the increased anti-
tumoral NK cell efficacy, when it is used with chemotherapeutic
approaches like gemcitabine or cyclophosphamide, which are well
known immunomodulatory agents with selective depletion effects
on immunosuppressive populations like MDSCs or regulatory T
cells (Treg), respectively (86, 96, 97). It was also demonstrated
that a novel oncolytic rhabdovirus (Maraba MG1) was able to
boost NK cell activity for the reduction of postoperative metas-
tases (98). Intriguingly, the authors revealed that the effect of NK
cell activation was mediated via virus infection of conventional
DC. This interaction refers to the important function of DC as
functional interface to innate immune effector cells for triggering
adaptive immune responses. It is known from patients treated with
cetuximab that NK cells are involved in antibody-dependent cyto-
toxicity of tumor cells and assist DCs in priming of antitumoral
T cell responses by an NK:DC crosstalk (99). This aspect could
be relevant in oncolytic virotherapy since antibody-mediated cell
killing of tumor cells has already been shown to play a yet under-
estimated role in human patients who have been treated with an
oncolytic vaccinia virus (100).
TREGS AND TREG DEPLETION DURING ONCOLYSIS: GOOD
OR BAD?
Regulatory CD4 T cells (Tregs) are an immunosuppressive cell
population that has frequently been discussed as a critical con-
tributor to the tumor microenvironment. It has been shown that
the ratio of intratumoral cytotoxic T cells and Tregs is a prognos-
tic factor for the patient’s outcome and studies using antibodies
blocking CTLA-4 (which is expressed on Tregs) for increased
immune activation have shown that Tregs can be interesting tar-
gets for immunotherapeutic approaches (101, 102). The impact
of viral infections on Tregs has been mostly studied in persistent
or chronic virus infection, such as HCV or HBV whereas the role
of Tregs during acute viral inflammations such as oncolytic virus
infections is much less investigated. Studies showed that the num-
ber of Tregs significantly drops during acute viral inflammation to
facilitate an effective antiviral immune response (103, 104).
To elicit enhanced immune stimulation, Treg depletion has
therefore been considered a supportive measure during oncolytic
virotherapy. Studies have shown that tumor preconditioning with
IL-2 and Treg depletion using a depleting antibody or low-dose
cyclophosphamide led to increased intratumoral uptake of sys-
temically delivered reovirus or vesicular stomatitis virus. IL-2 in
combination with Treg depletion generated “hyperactivated” NK
cells with enhanced antitumoral activity and secreting factors that
facilitated oncolytic virus spread throughout the tumor by dis-
rupting the tumor architecture (105, 106). Survival benefit by
this combination therapy was compromised when NK cells were
depleted. Additionally, Cheema et al. could reduce regulatory T
cell population in the tumor by arming an oHSV with the cytokine
IL12 leading to increased survival in a murine glioblastome stem
cell model. Survival benefit by additional expression of IL-12 was
absent in athymic mouse indicating that antitumoral efficacy was T
cell dependent (107). In contrast Treg depletion was demonstrated
to have even a negative therapeutic effect on VSV therapy by reliev-
ing Treg-mediated suppression of antiviral immunity resulting in
rapid clearance of the therapeutic vector (91).
However, the consequences of Treg depletion on long-term
antitumoral T cell responses that can be induced by oncolytic
virotherapy are not clear. Observations in classical infection mod-
els have shown that migratory activity of Tregs plays a central
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role in eliciting a protective immunity to viral infection (108).
Consistent with a positive function of Tregs in shaping antigen-
specific immune responses, we have observed that Treg deple-
tion abrogated the effective antitumoral T cell induction by an
oncolysis-assisted, antitumoral DC-vaccine (109). We could also
show that immunosuppressive MDSC expand in Treg-depleted
tumors, which may explain the failure of antitumoral T cell
priming. Supporting an important role of Tregs in the priming
of antigen-specific T cells, it has been described that Tregs can
undergo a conversion under acute inflammatory conditions to
adopt a T helper phenotype (110). Converted Tregs express proin-
flammatory cytokines and activate additional functions to provide
effective help for triggering T cell responses against new antigens.
These findings described above indicate that Tregs can essentially
modulate the course of tumor therapy with oncolytic viruses. A
supportive role of Treg depletion on virus spread and therapeutic
efficacy of oncolysis is still unclear and possible consequences on
induction of sustainable tumor-directed T cell responses require
further investigations.
HARNESSING ONCOLYTIC VIROTHERAPY AS
IMMUNOTHERAPY
Observations in immunocompromised xenografts have tempted
to overestimate the cytolytic effects that are achievable in human
patients. The situation in the immunocompetent host is com-
pletely different with positive and negative consequences for the
therapeutic efficacy of virotherapy. Since it is known that T cell
responses against cross-presented cellular antigens upon viral
infections trigger innate immune receptor pathways such as TLRs
and MyD88 (11, 12), investigations on corresponding antitumoral
immunity have been intensively pursued in oncolytic virus appli-
cations in immunocompetent models. The use of oncolytic VSV
in the B16-Ova model strikingly demonstrated that antitumoral
effects completely depended on Type I IFN responses, which
mediate both antiviral protection and antitumor therapy, whereas
VSV-mediated therapy was abolished in MyD88−/− mice (111).
The relevance of both innate immune activation and subsequent
triggering of adaptive responses was shown in experimental mod-
els with T cell depletion studies (10). Interesting observation have
been reported using herpes simplex virus variants with different
replicative properties. oHSV vectors that were more rapidly cleared
from the tumor but induced higher levels of DAMPs resulted in
best survival. This strongly indicates that replicative potency is
not the dominating factor as believed before but emphasizes the
impact of the initial immune induction (112), which needs to
be considered in the rational designs of novel approaches aim-
ing at increased antitumor immunity. DC are known to play a
crucial role in the generation of tumor-directed T cell responses
(113). First strategies on utilizing oncolytic virotherapy to engage
intrinsic activity of DC were performed with an ICP34.5 deleted
herpes simplex virus coding for GM-CSF (114). Tumor infec-
tion with this oncolytic virus led to regression and protected the
mice against rechallenge with tumor cells. GM-CSF-expressing
HSV then entered clinical development as OncoVexGM-CSF or
T-Vec (14, 115). Furthermore, virus-encoded GM-CSF not only
affected DCs, but also neutrophils which were shown to contribute
to antitumor effects by a GM-CSF-expressing oncolytic measles
virus in CD46 transgenic mice (70). The therapeutic benefit of
engaging dendritic cell activity in virotherapeutic applications was
confirmed using different cytokine setups. In a preclinical breast
cancer model, systemic, and intratumoral delivery of a TRAIL-
/E1A-expressing oncolytic adenovirus increased plasma levels of
TNFα, IFNγ, and MCP-1, proinflammatory cytokines acting as
maturation signals for DCs. Inclusion of FLT3L or GM-CSF-
expressing adenovirus for expansion of DCs established systemic
antitumor immunity and resulted in tumor elimination (116).
We obtained consistent results in a mouse model of lung can-
cer using intratumoral delivery of an oncolytic Ad combined
with vectors encoding FLT3L and MIP-1α. Tumor-directed T cells
were significantly increased and improved tumor responses were
obtained. However, adaptive immune responses against the viral
vector were also strongly enhanced suggesting that the balance
between tumor- and virus-directed immunity remains unaltered
instead of generating a favorable tumor-directed response (117).
Oncolytic viruses expressing cytokines for enhanced antigen cross
presentation illustrate that virotherapy can be used as a tool for a
generic in situ vaccination without the need for detailed informa-
tion about specific tumor-specific antigens. However, the approach
has limitations in shifting the predominant antiviral responses in
favor of antitumoral responses.
ONCOLYTIC VIROTHERAPY IN DC-VACCINATIONS AND
HETEROLOGOUS PRIME-BOOST SETTINGS
For focusing the immune system during virotherapy on the tumor
requires the incorporation of tumor-specific antigen targeting
approaches into the therapeutic scheme. We have investigated
this aspect by combining viral oncolysis and a tumor-directed
DC-vaccine (117). In another study, it has been shown that
a CCL5 (RANTES) expressing oncolytic vaccinia virus signif-
icantly improved the therapeutic efficacy of a tumor-directed
DC-vaccine (118). In a further study, it was demonstrated that the
application of a replicating adenovirus allowed for highly effec-
tive DC-vaccination, when the vaccine is administered exactly at
the time of apparent virus-induced tumor inflammation (109).
This approach induced potent cytotoxic T cell responses lead-
ing to significant tumor regression and complete eradication
of lung colonies in an aggressive tumor model that was oth-
erwise resistant to the DC-vaccine. A further promising direc-
tion is the development of oncolytic virus-based prime-boost
strategies that express the tumor-antigen. In a heterologous treat-
ment sequence with an adenoviral TAA-endoding vaccine and an
oncolytic VSV tumor expressing the same antigen significantly
enhanced tumor-directed CD8 T cell immune responses compared
to single treatments. Heterologous priming worked in both direc-
tions (119,120). This approach shifted the immune responses from
viral antigens to tumor-antigens and reduced viral replication in
healthy tissues thereby improving efficacy and safety. Interest-
ingly, the magnitude of tumor-specific responses after combina-
tion therapy was even higher in tumor-bearing hosts compared
to tumor-free mice indicating the need of infected tumor tis-
sue for priming antitumoral T cell reponses (120). The same
group could also demonstrate that heterologous boosting not only
resulted in higher numbers but also in functionally superior T cells
(121). A further interesting variation of prime-boost vaccinations
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comes from Brinkhoff and colleagues who elicited highest anti-
tumoral responses when the boost step by an antigen-expressing
infectious agent was preceded by a non-pathogenic prime using
antigen-loaded PLGA-microspheres (122).
TARGETING THE TUMOR ANTIGENOME ANDMUTANOME BY
ONCOLYTIC VIROTHERAPY
The use of complete antigen libraries encoded by an oncolytic
virus offers a promising approach to circumvent the limitations
of antigen-specific vaccinations. In a preclinical study in prostate
cancer, VSV-based cDNA libraries from xenogeneic healthy pros-
trate tissue were used for treatment of TC2 prostrate tumors.
Application of VSVs coding for such a cDNA library [Altered Self-
antigen and Epitope Library (ASEL)] cured established tumors
after repetitive intravenous injections. The use of ASEL conferred
significantly better protection against TC2 cells than a self-antigen
library from normal mouse prostate tissue. Upon application of
ASEL, a TH17 response was detectable and TC2 rejection was
dependent on CD4 cells, but not on CD8 T cells or NK cells
(123). A subsequent study from this group demonstrated that an
approach of virus-encoded melanoma cDNA libraries can be used
to identify tumor-associated antigens that have the ability to cure
melanoma (124). Virus-expressed cDNA libraries were effective
against melanoma thereby inducing only mild signs of autoim-
munity. The xenogenic, altered self-source is a precondition for
successful tumor treatment due to additional adjuvant effects com-
pared to a library from an autologous self-source. Again, the anti-
tumoral effect was correlated with a tumor-specific IL-17 response,
which was in turn utilized to screen for cDNA-viruses that induced
IL-17 memory for identification of tumor rejection antigens. After
validation of IL-17 inducing clones, three VSV-encoded tumor-
antigens were tested to treat established B16 tumors. Intriguingly,
injection of a single VSV-clone or a pool of two VSV-clones did
not show a therapeutic response, only the combination of all three
VSV-clones cured melanoma tumors to a similar extent as the
whole melanoma-library did. Although, it remains unclear why
only all three different TAA-coding VSVs contribute to therapeu-
tic effects, this finding suggest that applications targeting multiple
antigens at the same time should be preferred in immunothera-
peutic strategies. These studies establish a rational approach to
identify novel tumor-targets for immunotherapy and establish
an effective generic virus-based ASEL-vaccine for defined tumor
entities.
To date, identification of novel tumor-antigens that can be
addressed by targeted therapeutics appears to be a crucial step
toward the establishment of clinically effective immunothera-
pies and toward induction of sustained adaptive T cell responses.
In the past, antitumoral vaccine research has focused on find-
ing non-mutated, tumor-associated antigens such as telomerase
or MAGE, which can be found either in a relevant numbers of
patients and/or across several entities to promise broad applicabil-
ity. Disappointingly, corresponding vaccination approaches have
so far delivered insufficient effects in the clinic (125). A limit-
ing factor is that non-mutated tumor-antigens may not reflect
essential molecular functions required for tumor cell survival pro-
moting the generation of escape variants (126). Furthermore, T
cell precursors against this type of antigens are subject to thymus
selection and self-tolerance mechanisms thus limiting the num-
ber of required high-affinity T cell precursors that are essential
for effective antitumoral T cell responses. In this regard, trigger-
ing T cells that recognize immunogenic neoepitopes reflecting
tumor-associated mutated proteins could be a more promising
alternative. Data from melanoma patients indicate that autolo-
gous T cell responses to tumors are predominantly directed to
neoantigens (127). In murine models as well, tumor rejection
responses were also primarily induced by altered-self antigens
(128, 129). However, this would require individualized (personal-
ized) molecular diagnosis and therapy. Individual (solid) human
cancers usually harbor about 30 to more than hundred of protein-
encoded mutations referred to as mutanome (129–131), which
can be nowadays rapidly and cost-effectively analyzed by Next
Generation Sequencing (NGS) technology. Using this method,
non-synonymous single nucleotide variants (SNV) can be iden-
tified, representing promising candidates for immunotherapies,
since single amino acid variations in corresponding epitopes can
be processed and presented by MHC to T cells.
In a pioneering study targeting the mutanome by vaccina-
tions, NGS was used for immunoepitope identification in B16F10
melanoma cells. Selected from 563 non-synonymous SNV candi-
dates, the immunogenicity of 50 validated mutations was deter-
mined using corresponding peptide immunizations in mice. The
authors showed that immune responses could be raised against
60% of these epitopes and the vaccinations against these predicted
and validated epitopes successfully raised antitumoral adaptive
immune responses and significantly slowed tumor-growth (132).
This illustrates the great potential of this method in identifica-
tion of neoepitopes. However, the observation is also astonishing
since those epitopes should be per definition of low immuno-
genic nature. In clinically manifest tumors, the remaining epitope
spectrum is the result of a dynamic process termed cancer immu-
noediting, which acts on nascent tumors via different immune cell
types to protect against cancer development and shapes the tumor
at the same time toward decreased immunogenicity (129). In the
study by Castle and colleagues, the key for successful induction
of immune responses to immunoedited tumor-epitopes by DC-
vaccination is most likely attributable to the use of adjuvants, i.e.,
poly(I:C) in the B16F10 model. Oncolytic virotherapy is likewise
a potent trigger of innate immune receptors and inflammation
and could be an interesting tool that enables identification of
inflammation induced neoepitope-directed T cell responses and to
cooperate with tailored neoepitope-directed DC-vaccines. How-
ever, it will be a challenging task to identify neoepitope-specific T
cell reactivities that are involved in tumor responses induced by
oncolytic virotherapy.
ONCOLYTIC VIROTHERAPY AND IMMUNE CHECKPOINT
BLOCKADE
The recent clinical success of immune checkpoint blockade (133)
has confirmed the curative potential of tumor immunothera-
pies. Checkpoint blockade using ipilimumab, a CTLA-4-blocking
monoclonal antibody, has shown promising results in a phase
III study (134). Remarkably, responses seemed to include even
complete cures, but only a small proportion of patients bene-
fited from therapy. In a case study which described a patient with
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FIGURE 2 |The figure provides an overview on critical components to be included in multimodale virotherapy-based therapies that work like
prime-boost strategies.
advanced melanoma experiencing tumor response under ipili-
mumab, neoepitope analysis by NGS and epitope prediction led
to identification of a single ipilimumab-responsive neoepitope-
specific CD8 T cell that increased fivefold under therapy and
remained stable for a 10-month period (135). The fact, that only
one epitope was triggered in a tumor displaying 448 potential
T cell neoepitopes is remarkable but reflects that natural and
thus immunoedited tumors are low immunogenic despite harbor-
ing a high number of mutations and may also explain why only
small subgroups of patients respond to certain immunotherapies.
Oncolytic viruses can serve as an ideal tool to augment tumor
immunogenicity and could be ideally combined with immune
checkpoint blockade. Gao and colleagues have investigated the
application of a Her2/neu targeted oncolytic VSV in combination
with a CTLA-4 antibody in mice bearing Her2/neu transgenic
murine mammary tumors. This combination achieved cure in the
majority of mice whereas the virotherapy alone only prolonged
survival (136). Additionally, it has been tried to include an expres-
sion cassette for a CTLA-4-specific antibody into the backbone
of an oncolytic Ad to enhance local concentrations and to avoid
adverse events by systemic CTLA-4 inhibition (137). Recently, it
has been reported that injection of oncolytic NDV in a preclin-
ical model of B16 melanoma under CTLA-4 antibody treatment
induces an inflammatory response in tumor tissue, leading to lym-
phocytic infiltration and antitumor effect in distant, non-virally
injected tumors (138). Effective treatment induced activated CD4
and CD8 T cell infiltration in distant tumors and was dependent
on CD8+ cells, natural killer cells, and type I IFNs. Overcoming
systemic resistance to immune checkpoint blockade by oncolytic
virotherapy moreover led to protection from tumor rechallenge in
poorly immunogenic tumors, even in a cell line refractory to NDV-
mediated lysis. An alternative to checkpoint blockade is the direct
activation of costimulation using oncolytic viruses expressing the
costimulatory CD40L (53). Further approaches used oncolytic
vaccinia viruses expressing the ligand for the costimulatory recep-
tor 4-1BB (CD137) that achieved maximum antitumoral effi-
cacy in lymphodepleted hosts (139). Strong antitumoral immune
responses were also elicited by combining oncolytic vaccinia virus
with systemic application of a 4-1BB agonistic antibody (140). An
interesting immune checkpoint that has not yet been investigated
with virotherapy is PD-1/PD-L1. PD-1/PD-L1-blocking antibod-
ies are in a very promising clinical development (141). PD-
1/PD-L1 inhibition primarily activates antigen-experienced T cell
responses in the periphery, thus providing a mechanism that could
be promising to combine with virotherapeutic treatments.
PERSPECTIVE: ONCOLYTIC VIROTHERAPY IN MULTIMODALE
THERAPIES
There is increasing evidence that oncolytic virotherapy shows
antitumoral efficacy in clinical application even as monotherapy.
However, most preclinical data suggest that virotherapy can be
ideally combined with other treatment options to raise signifi-
cant therapeutic synergies on several levels (see also an overview
in Figure 2). First of all, oncolytic virus treatment needs to be
integrated in combined tumor-treatments leading to optimized
induction of ICD. Excellent reviews already exist on this aspect (16,
142, 143). Next step should be additional measures that amplify,
and prolong antitumoral immune responses. First data obtained
in humans and in murine melanoma models suggest significant
synergies when systemic immunotherapies, such as ipilimumab
and virotherapy are combined in a well-coordinated manner (138,
144). A very promising but clinically challenging point will be the
combination of viral oncolysis with surgical removal of the tumor.
Finally, it still needs further investigations to establish follow-up
therapies that work like classical boost strategies and may also pick
up personalized approaches such as NGS of tumors, epitope pre-
diction and and immunoanalysis in treated patients. Multimodal
therapy schemes will be a clue to establish virotherapy in the clinic.
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